EpiBiologics
San Mateo
About EpiBiologics
EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. The company provides an EpiTAC platform that enables the development of targeted therapies that degrade disease-driving membrane and extracellular proteins in a wide range of disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $203.1M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2026)
- Website: epibiologics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/epibiologics-3709 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.